SITC meeting overview of cancer immunotherapy and potential combination strategies within four key categories: Innate immunity, T cell activation, Tumor micro-environment, immune priming and boosting. Treatments are grouped in categories according to mechanism of action. Some of the listed products intervene in more than one category. A rational for combinations with elements taken from each of the different mechanistic categories should lead to optimized efficacy, while maybe minimizing autoimmune adverse effects. (CTX = cyclophosphamide, ARA = arabinoside, GEM = gemcitabine).